Evidence map›Paper›PMID 42212152›Full record

ArticleFrontiers in immunology2026

Data-driven computational modeling of CAR-T cell function.

Viren Shah, Justin A Womack, Katie Palen, Bryon D Johnson, Peiman Hematti, Tyce J Kearl, Nirav N Shah, Scott S Terhune, Ranjan K Dash

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Viren ShahDepartment of Biomedical Engineering, Medical College of Wisconsin, Milwaukee, WI, United States.
Justin A WomackDepartment of Biomedical Engineering, Medical College of Wisconsin, Milwaukee, WI, United States.
Katie PalenBlood and Marrow Transplant Program (BMT) and Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.
Bryon D JohnsonBlood and Marrow Transplant Program (BMT) and Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.
Peiman HemattiBlood and Marrow Transplant Program (BMT) and Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.
Tyce J KearlBlood and Marrow Transplant Program (BMT) and Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.
Nirav N ShahBlood and Marrow Transplant Program (BMT) and Cellular Therapy Program, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, United States.
Scott S Terhune *Department of Biomedical Engineering, Medical College of Wisconsin, Milwaukee, WI, United States.
Ranjan K Dash *Department of Biomedical Engineering, Medical College of Wisconsin, Milwaukee, WI, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The complex dynamics of chimeric antigen receptor T-cell (CAR-T cell) cytotoxicity and proliferation are potential factors that influence the clinical response to CAR-T therapy. The patient-specific functionality of CAR-T products play a role in these dynamics. CAR-T products comprise phenotypically and functionally distinct populations of cells that impact therapy response in different ways. We hypothesized that product-specific parameters exist that predict individual patient responses to therapy and that these can be elucidated by simulating the interactions of CAR-T products and tumor cells using an Methods: We use an ordinary differential equation (ODE)-based pharmacokinetic (PK) and pharmacodynamic (PD) model to characterize key CAR-T cell functional parameters. Parameters for the model developed using our method are product-specific and derived from Results: Our results demonstrate that while considerable variability is present in Conclusions: Overall, our work demonstrates that while pre-treatment CAR-T cell functional parameters vary on a patient and product basis, these parameters do not predict initial therapeutic responses. We find that initial therapeutic responses are possible across a range of initial product kinetic parameters. However, we observed that their potentially exist unique kinetic properties associated with the initial product that is predictive of disease relapse.

Indexed as

Computer SimulationImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesCytotoxicity, ImmunologicHumansReceptors, Chimeric AntigenCAR-T cell cytotoxicity kineticsCAR-T cellsCAR-T cellular differentiationCAR-T therapychimeric antigen receptorcomputational modelingmathematical modeling

Identifiers

PMID42212152
PMCPMC13212496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.